GlassScriptPhysician profile
Patrick S Zimmermann
NPI 1194749218
$1,127.14
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $113 · 2021: $13.80 · 2023: $70.37 · 2024: $194 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217.10 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $99.51 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $96.13 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $80.39 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $78.13 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.27 | 2019-2025 | Relistor, Xifaxan |
| Merck Sharp & Dohme LLC | $62.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.63 | 2019-2024 | |
| Glaxosmithkline, LLC. | $47.90 | 2023-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $32.29 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.58 | 2019 | |
| Astellas Pharma US INC | $27.33 | 2023 | Veozah |
| Allergan, INC. | $27.00 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $20.10 | 2024 | Ycanth |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $20.04 | 2019 | |
| Amarin Pharma, INC. | $18.96 | 2020 | |
| Shire North American Group INC | $15.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.93 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.80 | 2021 | |
| Viatris Specialty LLC | $13.65 | 2025 | Yupelri |
| Antares Pharma, INC. | $13.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Zimmermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.